Amgen’s Positive Denosumab Pivotal Trial Reduces Overhangs For Firm
This article was originally published in The Pink Sheet Daily
Executive Summary
Big biotech needs the potential $2.4 billion analysts estimate the bone-building drug could bring by 2016.